Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany

Respiratory Medicine

Volumn 104, Issue 1, 2010, Pages 142-148

  Reck, Martin ^a   Stahel, Rolf A ^b   von Pawel, Joachim ^c   Karthaus, Meinolf ^d   Korfee, Soenke ^e   Serke, Monika ^f   Schuette, Wolfgang H W ^g   Eschbach, Corinna ^h   Fink, Thomas H ⁱ   Leschinger, Monika I ^j   Manegold, Christian ^k  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Asklepios Hospital Gauting   (Germany)

^d Klinikum Neuperlach   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^g Hospital Martha Maria   (Germany)

^h Asklepios Klinik Hamburg Harburg   (Germany)

ⁱ University Hospital Nuremberg   (Germany)

^j LILLY DEUTSCHLAND GMBH   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Carboplatin; Cisplatin; Expanded access; Pemetrexed; Pleural mesothelioma

Indexed keywords

CARBOPLATIN; CISPLATIN; PEMETREXED;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PERITONEUM; PLEURA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 73749083400     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.07.019     Document Type: Article

References (23)

1. Sugarbaker P.H., Yan T.D., Stuart O.A., and Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32 (2006) 686-691
2. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 (2005) 1591-1603
3. Bani-Hani K.E., and Gharaibeh K.A. Malignant peritoneal mesothelioma. J Surg Oncol 91 (2005) 17-25
4. Papi M., Genestreti G., Tassinari D., et al. Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori 91 (2005) 276-279
5. Al-Qahtani M., Morris B., Dawood S., and Onerheim R. Malignant mesothelioma of the tunica vaginalis. Can J Urol 14 (2007) 3514-3517
6. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
7. Pelucchi C., Malvezzi M., La Vecchia C., et al. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 90 (2004) 1022-1024
8. Deutsches Mesotheliomregister [German Mesothelioma Registry]. www.bergmannsheil.de/788.0.html. [accessed 04.11.08].
9. Robinson B.W., Musk A.W., and Lake R.A. Malignant mesothelioma. Lancet 366 (2005) 397-408
10. Scagliotti G.V., Shin D.M., Kindler H.L., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
11. Thödtmann R., Depenbrock H., Dumez H., et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17 (1999) 3009-3016
12. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
13. Taylor P., Castagneto B., Dark G., et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 3 (2008) 764-771
14. Santoro A., O'Brien M.E., Stahel R.A., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 3 (2008) 756-763
15. Cancer Therapy Evaluation Program, National Cancer Institute, US National Institutes of Health. Common Toxicity Criteria (CTC), Version 2.0. http://ctep.cancer.gov./forms/CTCv20_4-30-992.pdf. [accessed 18.01.08].
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the Unites States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. Karthaus M., Frieler F., Plahl A., et al. Pemetrexed +/- platinum for patients with malignant peritoneal mesothelioma: the Bielefeld experience (2006), ASCO GI Meeting A169
18. Jänne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J., Polikoff J.A., Mintzer D.M., Taylor L., Ashland J., Ye Z., Monberg M.J., and Obasaju C.K. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Canc 7 (2005) 40-46
19. Obasaju C.K., Ye Z., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J., Polikoff J.A., Mintzer D.M., Monberg M.J., and Jänne P.A. Pemetrexed Expanded Access Program Investigators. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 55 (2007) 187-194
20. Jänne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J., Polikoff J.A., Mintzer D.M., Ye Z., Monberg M.J., and Obasaju C.K. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 1 (2006) 506-512
21. Jassem J., Ramlau R., Santoro A., Schuette W., Chemaissani A., Hong S., Blatter J., Adachi S., Hanauske A., and Manegold C. Phase III trial comparing pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26 (2008) 1698-1704
22. Sørensen J.B., Sundstrøm S., Perell K., and Thielsen A.K. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2 (2007) 147-152
23. van den Bogaert D.P., Pouw E.M., van Wijhe G., et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 1 (2006) 25-30